Develops two novel classes of water‑soluble small‑molecule oncology drugs — antiangiogenic/anti‑tubulin (AA/AT) and folate‑targeted anti‑cancer (FTAC) compounds — aimed at treating multiple cancer types with improved safety and efficacy in vivo.